Table of Content

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Global Non-Small-Cell Lung Cancer Market Outlook
4.1. Market Size & Forecast
4.1.1. By Value
4.2. Market Share & Forecast
4.2.1. By Type (Squamous Cell Carcinoma, Large Cell Carcinoma, Adenocarcinoma, Others)
4.2.2. By Drug Class (Epidermal Growth Factor Receptor (EGFR) Inhibitors, Anaplastic Lymphoma Kinase (ALK) Inhibitors, ROS1 Inhibitors, BRAF Inhibitors, Others)
4.2.3. By Treatment (Chemotherapy, Targeted Therapy, Immunotherapy)
4.2.4. By End-user (Hospitals & Clinics, Ambulatory Care Centers, Others)
4.2.5. By Region
4.2.6. By Company (2022)
4.3. Market Map
4.3.1. By Type
4.3.2. By Drug Class
4.3.3. By Treatment
4.3.4. By End-user
4.3.5. By Region
5. Asia Pacific Non-Small-Cell Lung Cancer Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Type
5.2.2. By Drug Class
5.2.3. By Treatment
5.2.4. By End-user
5.2.5. By Country
5.3. Asia Pacific: Country Analysis
5.3.1. China Non-Small-Cell Lung Cancer Market Outlook
5.3.1.1. Market Size & Forecast
5.3.1.1.1. By Value
5.3.1.2. Market Share & Forecast
5.3.1.2.1. By Type
5.3.1.2.2. By Drug Class
5.3.1.2.3. By Treatment
5.3.1.2.4. By End-user
5.3.2. India Non-Small-Cell Lung Cancer Market Outlook
5.3.2.1. Market Size & Forecast
5.3.2.1.1. By Value
5.3.2.2. Market Share & Forecast
5.3.2.2.1. By Type
5.3.2.2.2. By Drug Class
5.3.2.2.3. By Treatment
5.3.2.2.4. By End-user
5.3.3. Australia Non-Small-Cell Lung Cancer Market Outlook
5.3.3.1. Market Size & Forecast
5.3.3.1.1. By Value
5.3.3.2. Market Share & Forecast
5.3.3.2.1. By Type
5.3.3.2.2. By Drug Class
5.3.3.2.3. By Treatment
5.3.3.2.4. By End-user
5.3.4. Japan Non-Small-Cell Lung Cancer Market Outlook
5.3.4.1. Market Size & Forecast
5.3.4.1.1. By Value
5.3.4.2. Market Share & Forecast
5.3.4.2.1. By Type
5.3.4.2.2. By Drug Class
5.3.4.2.3. By Treatment
5.3.4.2.4. By End-user
5.3.5. South Korea Non-Small-Cell Lung Cancer Market Outlook
5.3.5.1. Market Size & Forecast
5.3.5.1.1. By Value
5.3.5.2. Market Share & Forecast
5.3.5.2.1. By Type
5.3.5.2.2. By Drug Class
5.3.5.2.3. By Treatment
5.3.5.2.4. By End-user
6. Europe Non-Small-Cell Lung Cancer Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type
6.2.2. By Drug Class
6.2.3. By Treatment
6.2.4. By End-user
6.2.5. By Country
6.3. Europe: Country Analysis
6.3.1. France Non-Small-Cell Lung Cancer Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Type
6.3.1.2.2. By Drug Class
6.3.1.2.3. By Treatment
6.3.1.2.4. By End-user
6.3.2. Germany Non-Small-Cell Lung Cancer Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Type
6.3.2.2.2. By Drug Class
6.3.2.2.3. By Treatment
6.3.2.2.4. By End-user
6.3.3. Spain Non-Small-Cell Lung Cancer Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Type
6.3.3.2.2. By Drug Class
6.3.3.2.3. By Treatment
6.3.3.2.4. By End-user
6.3.4. Italy Non-Small-Cell Lung Cancer Market Outlook
6.3.4.1. Market Size & Forecast
6.3.4.1.1. By Value
6.3.4.2. Market Share & Forecast
6.3.4.2.1. By Type
6.3.4.2.2. By Drug Class
6.3.4.2.3. By Treatment
6.3.4.2.4. By End-user
6.3.5. United Kingdom Non-Small-Cell Lung Cancer Market Outlook
6.3.5.1. Market Size & Forecast
6.3.5.1.1. By Value
6.3.5.2. Market Share & Forecast
6.3.5.2.1. By Type
6.3.5.2.2. By Drug Class
6.3.5.2.3. By Treatment
6.3.5.2.4. By End-user
7. North America Non-Small-Cell Lung Cancer Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type
7.2.2. By Drug Class
7.2.3. By Treatment
7.2.4. By End-user
7.2.5. By Country
7.3. North America: Country Analysis
7.3.1. United States Non-Small-Cell Lung Cancer Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Type
7.3.1.2.2. By Drug Class
7.3.1.2.3. By Treatment
7.3.1.2.4. By End-user
7.3.2. Mexico Non-Small-Cell Lung Cancer Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Type
7.3.2.2.2. By Drug Class
7.3.2.2.3. By Treatment
7.3.2.2.4. By End-user
7.3.3. Canada Non-Small-Cell Lung Cancer Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Type
7.3.3.2.2. By Drug Class
7.3.3.2.3. By Treatment
7.3.3.2.4. By End-user
8. South America Non-Small-Cell Lung Cancer Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Type
8.2.2. By Drug Class
8.2.3. By End-user
8.2.4. By Country
8.3. South America: Country Analysis
8.3.1. Brazil Non-Small-Cell Lung Cancer Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Type
8.3.1.2.2. By Drug Class
8.3.1.2.3. By Treatment
8.3.1.2.4. By End-user
8.3.2. Argentina Non-Small-Cell Lung Cancer Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Type
8.3.2.2.2. By Drug Class
8.3.2.2.3. By Treatment
8.3.2.2.4. By End-user
8.3.3. Colombia Non-Small-Cell Lung Cancer Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Type
8.3.3.2.2. By Drug Class
8.3.3.2.3. By Treatment
8.3.3.2.4. By End-user
9. Middle East and Africa Non-Small-Cell Lung Cancer Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Type
9.2.2. By Drug Type
9.2.3. By Treatment
9.2.4. By End-user
9.2.5. By Country
9.3. MEA: Country Analysis
9.3.1. South Africa Non-Small-Cell Lung Cancer Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Type
9.3.1.2.2. By Drug Class
9.3.1.2.3. By Treatment
9.3.1.2.4. By End-user
9.3.2. Saudi Arabia Non-Small-Cell Lung Cancer Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Type
9.3.2.2.2. By Drug Type
9.3.2.2.3. By Treatment
9.3.2.2.4. By End-user
9.3.3. UAE Non-Small-Cell Lung Cancer Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Type
9.3.3.2.2. By Drug Class
9.3.3.2.3. By Treatment
9.3.3.2.4. By End-user
9.3.4. Egypt Non-Small-Cell Lung Cancer Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By Type
9.3.4.2.2. By Drug Class
9.3.4.2.3. By Treatment
9.3.4.2.4. By End-user
10. Market Dynamics
10.1. Drivers
10.2. Challenges
11. Market Trends & Developments
11.1. Recent Developments
11.2. Product Launches
11.3. Mergers & Acquisitions
12. Global Iron Deficiency Anemia: SWOT Analysis
13. Porter?s Five Forces Analysis
13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Product
14. Competitive Landscape
14.1. Eli Lilly and Company
14.1.1. Business Overview
14.1.2. Company Snapshot
14.1.3. Products & Services
14.1.4. Current Capacity Analysis
14.1.5. Financials (In case of listed)
14.1.6. Recent Developments
14.1.7. SWOT Analysis
14.2. Sanofi SA
14.3. Novartis AG
14.4. F. Hoffmann-La Roche Ltd
14.5. Merck & Co., Inc.
14.6. Pfizer Inc.
14.7. AstraZeneca Plc
14.8. Boehringer Ingelheim Inc.
14.9. Bristol-Myers Squibb Company
14.10. Astellas Pharma
15. Strategic Recommendations
16. About Us & Disclaimer